Norway
Norway is an unitary parliamentary constitutional monarchy. The official languages are Norwegian and a variation; New-Norwegian.
The Norwegian government is providing good and equal health and care services for the population of Norway. All citizens are covered by an insurance program paid by the government.
Pricing of pharmaceuticals are regulated, and reimbursement system is different for GP, - and hospital products.
Healthcare budget
$35 billion
Inhabitants
5.3 million
GDP per capita
$83.871
Currency
NOK (1 NOK = 0,10 Euro)
World Ranking
GDP 33th
Norwegian healthcare
The healthcare in Norway is rated as number three by EuroHealth Consumer Index 2018.
Norway is one of the top spenders on health care among OECD countries in per capita terms but much closer to the average when seen as a share of GDP.
According to OECD Health Statistics 2019, the healthcare spending related to GDP in Norway was 10,2% (2018).
Norwegian pharmaceutical environment
Norway has price reference system, which secure a low-price level of pharmaceuticals.
In 2017 the total spending for pharmaceuticals was $ 2,1 billion, of this 8% for OTC-products.
In 2016 the spending for hospital medicines was $ 0,43 billion.
The National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway was launched in 2013. This system aims to provide an appropriate decision-making platform for priority setting based on HTAs. This system makes the decisions independently of the Drug Agency in Norway.
Today’s challenges
The population is growing, getting older and need more healthcare.
The new and expensive medicines cause a significantly rise in the cost of pharmaceuticals the last years.
At hospitals, one-to one meetings are no longer an option. Pre-booked group-meetings is the standard.
The experts in Norway
Karin Torberger & Clas Lindbergson
Challenge us with your case and we will show you the possibilities for your product.
Services
Sales and Marketing
Entering the European market is not easy. Up to 51 countries with different healthcare systems. What is your strategy? Apart from the Big-5, what do you do with the other 28 countries? We offer a solution for 28 countries. Sales and marketing is our core business.
Learn moreDistribution
We manage, through our logistic partners with their regional warehouses, the distribution to our region (28 countries). They have the capability to handle the most demanding of specialized product order management, storage, handling and distribution requirements.
Learn moreEarly Market Research
You know that market research is critical. It provides customer insights, competitive intelligence, behavioural tendencies, and product positioning. And market research increasingly is becoming an important component for linking R&D and marketing teams.
Learn moreMarket Access
Achieving reimbursement and getting the right price are the 2 most important drivers for a successful launch of an innovative pharmaceuticals in our part of Europe. Health Authorities in any European country decide individually based on their local regulations, policies, framework, social values and available health care budget.
Learn moreMarket Authorisation
Unlike other regions, in the EU a number of options is available to obtain a marketing authorisation. Centralised at the European Medicines Agency in Amsterdam or decentralised with the individual competent authorities of the member states, each marketing authorisation application procedure has its pros and cons. In the case of Switzerland, it has its own regulatory authority, Swissmedic, and processes.
Learn morePharmacovigilance
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.
Learn more